Michael R McClung1,2. 1. Institute of Health and Ageing, Australian Catholic University, Melbourne, VIC, Australia. mmcclung.ooc@gmail.com. 2. Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR, 97210, USA. mmcclung.ooc@gmail.com.
Abstract
PURPOSE OF REVIEW: The objective of this review is to update evidence regarding the use of osteoporosis drugs in sequence or in combination to optimize increases in bone mass and strength. RECENT FINDINGS: Simultaneous use of denosumab plus teriparatide produces larger increases in BMD than does monotherapy. The use of bisphosphonates or denosumab after teriparatide results in progressive gains in BMD. When switching from bisphosphonates and especially denosumab to teriparatide, an overlap of 6-12 months may prevent the transient loss of BMD in cortical sites. Phase 3 trials document fracture risk reduction with anabolic therapy for 12-18 months followed by an anti-remodeling drug. With the exception of adding teriparatide to ongoing denosumab therapy, there is little evidence to support the use of more than one osteoporosis drug at a time. In contrast, sequential therapy regimens of anabolic drugs followed by potent anti-remodeling agents will be the new standard for treating patients at imminent risk of fracture.
PURPOSE OF REVIEW: The objective of this review is to update evidence regarding the use of osteoporosis drugs in sequence or in combination to optimize increases in bone mass and strength. RECENT FINDINGS: Simultaneous use of denosumab plus teriparatide produces larger increases in BMD than does monotherapy. The use of bisphosphonates or denosumab after teriparatide results in progressive gains in BMD. When switching from bisphosphonates and especially denosumab to teriparatide, an overlap of 6-12 months may prevent the transient loss of BMD in cortical sites. Phase 3 trials document fracture risk reduction with anabolic therapy for 12-18 months followed by an anti-remodeling drug. With the exception of adding teriparatide to ongoing denosumab therapy, there is little evidence to support the use of more than one osteoporosis drug at a time. In contrast, sequential therapy regimens of anabolic drugs followed by potent anti-remodeling agents will be the new standard for treating patients at imminent risk of fracture.
Authors: Felicia Cosman; Erik Fink Eriksen; Chris Recknor; Paul D Miller; Núria Guañabens; Christian Kasperk; Philemon Papanastasiou; Aimee Readie; Hanumantha Rao; Jürg A Gasser; Christina Bucci-Rechtweg; Steven Boonen Journal: J Bone Miner Res Date: 2011-03 Impact factor: 6.741
Authors: S T Harris; E F Eriksen; M Davidson; M P Ettinger; A H Moffett; D J Baylink; C E Crusan; A A Chines Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Marcella D Walker; Natalie E Cusano; James Sliney; Megan Romano; Chiyuan Zhang; Donald J McMahon; John P Bilezikian Journal: Endocrine Date: 2012-10-26 Impact factor: 3.633
Authors: Benjamin Z Leder; Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Yuli Zhu; Katelyn Foley; Hang Lee; Robert M Neer Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958
Authors: Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958
Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Richard D Wasnich; Yu Z Bagger; David J Hosking; Michael R McClung; Mei Wu; Ann Marie Mantz; John J Yates; Philip D Ross; Peter Alexandersen; Pernille Ravn; Claus Christiansen; Arthur C Santora Journal: Menopause Date: 2004 Nov-Dec Impact factor: 2.953
Authors: P D Miller; N Pannacciulli; J P Brown; E Czerwinski; B S Nedergaard; M A Bolognese; J Malouf; H G Bone; J-Y Reginster; A Singer; C Wang; R B Wagman; S R Cummings Journal: J Clin Endocrinol Metab Date: 2016-06-06 Impact factor: 5.958
Authors: M R McClung; M A Bolognese; J P Brown; J-Y Reginster; B L Langdahl; J Maddox; Y Shi; M Rojeski; P D Meisner; A Grauer Journal: Osteoporos Int Date: 2020-07-04 Impact factor: 4.507